Results 271 to 280 of about 55,913 (304)

Meningococcal conjugate vaccines

Expert Opinion on Pharmacotherapy, 2004
Neisseria meningitidis is a leading cause of bacterial meningitis and sepsis in the US, Europe and in many other parts of the world, including parts of sub-Saharan Africa (known as the African 'meningitis belt'). There are > 500000 cases of meningococcal disease annually with an estimated death toll of 135000 worldwide.
David S. Stephens, Shanta M. Zimmer
openaire   +3 more sources

CONJUGATED POLYSACCHARIDE VACCINES

Infectious Disease Clinics of North America, 1999
The joining of polysaccharide antigens to various proteins can result in increased immunogenicity of vaccines composed of such antigens. This article discusses conjugated polysaccharide vaccines for Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitis.
Edward K. Chapnick, Hussain Ahmad
openaire   +3 more sources

Pneumococcal conjugate vaccines

Immunology Letters, 1991
We have prepared conjugates of pneumococcal type 4 polysaccharides (PS4) or oligosaccharides to tetanus toxoid using the carbodiimide method. The use of a spacer, 6-aminohexanoic acid, resulted in higher incorporation of carrier protein. Conjugates contained up to 10% free polysaccharide, but no free protein.
Bart L. Haagmans, Ger T. Rijkers, Dolf Evenberg, Ben J.M. Zegers, Anne-Marie Tenbergen-Meekes, Jan Poolman, Carla C. A. M. Peeters   +6 more
openaire   +2 more sources

Combination conjugate vaccines

Expert Opinion on Drug Safety, 2006
Increasingly, more diseases are becoming vaccine preventable, but maintaining community and provider acceptance demands that the number of injections does not increase. Combination conjugate vaccines represent an inevitable and important advance. This paper reviews the efficacy and safety of combination conjugate vaccines, including immunological ...
Jim Buttery, Naor Bar-Zeev
openaire   +3 more sources

Pneumococcal conjugate vaccine

Current Opinion in Pediatrics, 2001
Pneumococcal infections account for a significant proportion of bacterial infections in infants and children. The growing threat from pneumococci resistant to penicillin and other antimicrobials has led to increased pressure for the development of an effective vaccine.
openaire   +2 more sources

Conjugated Heptavalent Pneumococcal Vaccine

The Annals of Pharmacotherapy, 2002
OBJECTIVE: To review the immunogenicity, efficacy, and safety of the heptavalent conjugated pneumococcal vaccine (PCV7). DATA SOURCES: A MEDLINE search (1993–August 2001) of research limited to humans published in the English language was conducted. STUDY SELECTION: Findings from randomized, controlled, multicenter trials were reviewed.
Vinita B. Pai, John Erramouspe, Catherine A Heyneman   +2 more
openaire   +3 more sources

Meningococcal conjugate vaccines

Expert Opinion on Biological Therapy, 2005
Disease caused by Neisseria meningitidis is associated with high mortality rates and significant sequelae. Polysaccharide meningococcal vaccines have been available for > 20 years, and have been used in travellers to control outbreaks, and in some countries for adolescents entering college, although they provide only a short duration of immunity and do
openaire   +3 more sources

Glycoprotein conjugate vaccines

Vaccine, 1999
The polysaccharide capsule which surrounds bacterial species like Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Salmonella typhi, is a potent virulence factor. It protects the bacterium from phagocytosis, but capsule specific antibodies plus complement binding to the capsule opsonise the organism for phagocytosis and ...
openaire   +3 more sources

The promise of conjugate vaccines for Africa

Vaccine, 2007
Capsular polysaccharide (PS) vaccines against Neisseria meningitidis and Streptococcus pneumoniae have proven safe and effective. Moreover, experience with N. meningitidis, Haemophilus influenzae type b (Hib) and S. pneumoniae conjugate vaccines has demonstrated that immunogenicity of PS vaccines can be greatly improved by chemical conjugation to a ...
Marie Paule Kieny, F. Marc LaForce
openaire   +3 more sources

[Conjugate vaccines].

Revue medicale de Bruxelles, 2002
Conjugate vaccines extend the vaccinal prevention for children to more diseases. Conjugating the capsular polysaccharide to a carrier protein transforms a T-independent antigen in a T-dependent, allowing protection of the children (before 2 years of age) against Haemophilus influenzae type b, meningococcal C and pneumococcal infections.
B, Swennen, J, Sternon
openaire   +2 more sources